Fresenius
Fresenius is a global healthcare group specializing in products and services for critically and chronically ill patients, with a significant presence in Europe and the U.S. through its subsidiaries Fresenius Kabi and Fresenius Helios.
Services
Fresenius provides a wide range of services primarily focusing on healthcare. Fresenius Kabi specializes in products for chronically and critically ill patients, offering biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Fresenius Helios operates as Europe’s leading private healthcare provider with 87 hospitals in Germany and 56 in Spain and Latin America, delivering advanced treatments including proton beam therapy and minimally invasive procedures using Da Vinci surgical robots.
Products
Fresenius Kabi has a robust product lineup, which includes Tyenne®, a biosimilar for tocilizumab available in both IV and subcutaneous formulations. Its portfolio also features Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan used in cancer treatment. The company is active in developing a pipeline of autoimmune and oncology biosimilars with several molecules in late-stage development. Their range includes parenteral nutrition products, addressing essential nutritional needs in critically ill patients.
Sustainability Initiatives
Fresenius is committed to sustainability and has an independent advisory board to oversee its initiatives. The company aims to be climate neutral by 2040, with intermediate targets to reduce absolute scope 1 and scope 2 emissions by 50% by 2030, compared to 2020 levels. These efforts align with Fresenius' broader goal to operate sustainably and responsibly within the healthcare industry.
History of Fresenius Helios
Fresenius Helios has become Europe's leading private healthcare provider, operating a significant number of hospitals—87 in Germany and another 56 across Spain and Latin America. The division treats millions of patients annually, offering advanced medical procedures such as proton beam therapy in Spain and using Da Vinci surgical robots for minimally invasive surgeries in Germany. This expansion and technological adoption highlight Fresenius Helios' pivotal role in the European healthcare sector.
Fresenius Kabi's Market Presence
Fresenius Kabi holds a significant market position, particularly in China, where it operates four manufacturing plants and leads in the parenteral nutrition sector. The business unit has demonstrated growth potential, marked by its Biopharma business achieving EBIT break-even in Q1/24. Its product growth vectors include a focus on MedTech, Nutrition, and Biopharma, supporting healthcare professionals and patients with a comprehensive holistic support program in the U.S.